This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Quality of Care  • Evidence-Based Medicine  • Statistics and Research Methods  • Women's Health  • Women's Health, Other  • Diagnosis  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Kathryn A. Phillips, PhD

JAMA. 2008;300(21):2542-2544.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

New testing technologies—increasingly based on genomic information—are essential in the shift toward personalized medicine and molecular targeted therapies. Considering the rapid proliferation of new tests, health care insurers and policy makers are interested in assessing evidence about their use and value.

It is critical to build an evidence base to support effective decision making related to testing technologies as they are used in clinical practice. The example of human epidermal growth factor receptor 2 (HER2, or ERBB2) testing for breast cancer illustrates the challenges and opportunities. Many groups, including the Institute of Medicine, Agency for Healthcare Research and Quality, Secretary's Advisory Committee on Genetics, Health, and Society, President's Council of Advisors on Science and Technology, and Evaluation of Genomic Applications in Practice and Prevention Project, have cited the need to improve the evidence base for genomic and testing technologies. This Commentary extends previous work, emphasizing the . . . [Full Text of this Article]

Why HER2 Testing Illustrates the Evidence Gap

Author Affiliations: Center for Translational and Policy Research on Personalized Medicine, School of Pharmacy, Philip R. Lee Institute for Health Policy Studies, and UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?